Bonfardeci G, Cimminiello C, Cantini L, Arpaia G, Aloisio M, Pozzi F
San Carlo Borromeo General Hospital, Milan, Italy.
Int Angiol. 1994 Dec;13(4):339-42.
The activity of trapidil, an antiaggregating agent with PDGF antagonist properties, was investigated in order to verify its possible modulating effect in the endothelial and platelet activation. PDGF, t-PA, PAI-1 and ET-1 plasma levels were measured before and after a 2 month treatment period with trapidil 200 mg tablets bid or placebo in 30 patients affected by POA in Fontaine stage II. PDGF and PAI-1 significantly (p < 0.05) increased in the placebo group, and PDGF also in the comparison between treatments (p < 0.05). Aggregation data demonstrate an absence of Ca++ antagonist action of trapidil. The results of this study suggest that trapidil can interfere with the combined vascular and platelet response in atherogenesis.
为了验证曲匹地尔（一种具有血小板衍生生长因子拮抗剂特性的抗聚集剂）在内皮细胞和血小板激活过程中可能的调节作用，对其活性进行了研究。在30例处于Fontaine II期的周围动脉闭塞症（POA）患者中，测量了他们在接受为期2个月的每日两次200 mg曲匹地尔片或安慰剂治疗前后的血小板衍生生长因子（PDGF）、组织型纤溶酶原激活剂（t-PA）、纤溶酶原激活物抑制剂-1（PAI-1）和内皮素-1（ET-1）的血浆水平。在安慰剂组中，PDGF和PAI-1显著升高（p < 0.05），在不同治疗方法的比较中，PDGF也升高（p < 0.05）。聚集数据表明曲匹地尔不存在钙离子拮抗剂作用。本研究结果提示，曲匹地尔可干扰动脉粥样硬化形成过程中血管和血小板的联合反应。
